The book focuses on two concurrent experimental therapies in cancer treatment known as boron neutron capture therapy (BNCT) and gadolinium neutron capture therapy (GdNCT) using a variety of boron- and gadolinium-based compounds. Some of the gadolinium compounds serve the dual purpose as being MRI contrast agents and GdNCT agents. The book describes why BNCT & GdNCT were not at the forefront of the clinical trials during the past seven to eight decades since the discovery of neutrons by John Chadwick in 1932 and how the latest development in the synthesis of target boron- and gadolinium-based drugs has turned the area into the hottest one worthy of further investigation with the new clinical trials in the USA and elsewhere.

The book focuses on two concurrent experimental therapies in cancer treatment known as boron neutron capture therapy (BNCT) and gadolinium neutron capture therapy (GdNCT) using a variety of boron- and gadolinium-based compounds. Some of the gadolinium compounds serve the dual purpose as being MRI contrast agents and GdNCT agents. The book describes why BNCT & GdNCT were not at the forefront of the clinical trials during the past seven to eight decades since the discovery of neutrons by John Chadwick in 1932 and how the latest development in the synthesis of target boron- and gadolinium-based drugs has turned the area into the hottest one worthy of further investigation with the new clinical trials in the USA and elsewhere.

Neutron capture therapy (NCT) is based on the ability of the non-radioactive isotope boron-10 to capture thermal neutrons with very high probability and immediately to release heavy particles with a path length of one cell diameter, which in principle allows for tumor cell-selective high-LET particle radiotherapy. This book provides a comprehensive summary of the progress made in NCT in recent years. Individual sections cover all important aspects, including neutron sources, boron chemistry, drugs for NCT, dosimetry, and radiation biology. The use of NCT in a variety of malignancies and also some non-malignant diseases is extensively discussed. NCT is clearly shown to be a promising modality at the threshold of wider clinical application. All of the chapters are written by experienced specialists in language that will be readily understood by all participating disciplines.

Noted experts review the current status of boron-containing drugs and materials for molecular medical diagnostics Boron-Based Compounds offers a summary of the present status and promotes the further development of new boron-containing drugs and advanced materials, mostly boron clusters, for molecular medical diagnostics. The knowledge accumulated during the past decades on the chemistry and biology of bioorganic and organometallic boron compounds laid the foundation for the emergence of a new area of study and application of boron compounds as lipophilic pharmacophores and modulators of biologically active molecules.This important text brings together in one comprehensive volume contributions from renowned experts in the field of medicinal chemistry of boron compounds. The authors cover a range of the most relevant topics including boron compounds as modulators of the bioactivity of biomolecules, boron clusters as pharmacophores or for drug delivery, boron compounds for boron neutron capture therapy (BNCT) and for diagnostics, as well as in silico molecular modeling of boron- and carborane-containing compounds in drug design. Authoritative and accessible, Boron-Based Compounds: Contains contributions from a panel of internationally renowned experts in the field Offers a concise summary of the current status of boron-containing drugs and materials used for molecular diagnostics Highlights the range and capacity of boron-based compounds in medical applications Includes information on boron neutron capture therapy and diagnostics Designed for academic and industrial scientists, this important resource offers the cutting-edge information needed to understand the current state of boron-containing drugs and materials for molecular medical diagnostics.

Boron Nitride Nanotubes in Nanomedicine compiles, for the first time in a single volume, all the information needed by researchers interested in this promising type of smart nanoparticles and their applications in biomedicine. Boron nitride nanotubes (BNNTs) represent an innovative and extremely intriguing class of nanomaterials. After introducing BNNTs and explaining their preparation and evaluation, the book shows how the physical, chemical, piezoelectric and biocompatibility properties of these nanotubes give rise to their potential uses in biomedicine. Evidence is offered (from both in vitro and in vivo investigations) for how BNNTs can be useful in biomedical and nanomedicine applications such as therapeutic applications, tissue regeneration, nanovectors for drug delivery, and intracellular nanotransducers. - Covers a range of promising biomedical BNNT applications - Provides great value not just to academics but also industry researchers in fields such as materials science, molecular biology, pharmacology, biomedical engineering, and biophysical sciences - Offers evidence for how BNNTs can be useful in biomedical and nanomedicine applications such as therapy, tissue regeneration, nanovectors for drug delivery, and intracellular nanotransducers - Incorporates, for the first time in a single volume, all the information needed by researchers interested in this promising type of smart nanoparticles and their applications in biomedicine

Binary systems for the treatment of cancer potentially are among the most attractive of the new therapeutic modalities that currently are under investigation. The basicconcept is to selectivelydestroy malignantcells whileconcomitantlysparing normal tissue. Neutron capture therapy (NCT) is the binary system that has been the subject of the Fifth International Symposium on Neutron Capture Therapy, which was held September13-17, 1992, in Columbus, Ohio, undertheauspicesoftheInternational Society for Neutron Capture Therapy. Its objective was to bring together researchers from throughout the world and to provide a forum at which they could present the latest advances in the development of Neutron capture therapy. Neutron capture therapy has largely, but not exclusively, focused on the use of boron-10 as the target nuclide. Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when the stable isotope, boron-10, absorbs low-energy non ionizing thermal neutrons to yield alphaparticles and recoiling lithium-7 nuclei. The size and energy of these high linear energy transfer (LET) particles result in their being confined largely to the cells in which the capture reaction occurs. For BNCT to be successful, a sufficient numberof I~atoms mustbe localized within neoplastic cells, and enough thermal neutrons must be delivered and absorbed by the I~ to produce a lethal 1~(n,QVLi reaction. Two major problems must be surmounted.

This book is organized into 12 important chapters that focus on the progress made by metal-based drugs as anticancer, antibacterial, antiviral, anti-inflammatory, and anti-neurodegenerative agents, as well as highlights the application areas of newly discovered metallodrugs. It can prove beneficial for researchers, investigators and scientists whose work involves inorganic and coordination chemistry, medical science, pharmacy, biotechnology and biomedical engineering.

The first part of this book summarizes the rationale and the preclinical data for combined treatment with ionizing radiation and pharmaceutical agents. Individual chapters focus on forms of combined treatment, with due consideration being given to a range of drugs and to emerging combinations with small molecules and antibodies. The second part comprises a series of disease-specific chapters in which the clinical results of combined modality treatment are presented.

This book reviews locoregional radionuclide cancer therapies (LRCT). Proving an increasingly viable alternative to radiotherapy, radionuclide therapy includes a diversity of choices of well characterized biochemical and physiologic target molecules. The delivery and retention of radionuclides may be monitored by advanced imaging for exact tissue localization and for real-time dosimetry to enable personalized precision medicine. Radiopharmaceuticals in human cancer therapies are typically delivered in systemic routes but can also be designed for locoregional routes to harness pharmacokinetic advantages of higher payload and lower systemic toxicities. This book explores the latest advancements and clinical considerations of the locoregional approach. Throughout the chapters, the clinical and scientific bases of cancer treatment and the locoregional use of radionculides are explored. Mathematical models of radiation dosimetry of locoregional radionculdies on tissues are studied using common models for multiple commercially available radionuclides. Rodent and canine tumor models of LRCT are compared for selected radionuclides and radiopharmaceuticals. The practical aspects of radiopharmaceuticals production, marketing, transport, as well as radiation protection are reviewed. Finally, the combination of LRCT with immunotherapy and other cancer therapies and prospective future use of LRCT are discussed. This is a guide for practicing nuclear physicians, interventional radiologists, radiation oncologists, radiation scientists, veterinarians and oncologists to expand their knowledge base and to prepare for designing locoregional radionuclide cancer therapies in animals and in humans.

A comprehensive, authoritative and up-to-date reference for the newcomer to radiopharmaceuticals and those already in the field. Radiopharmaceuticals are used to detect and characterise disease processes, or normal biological function, in living cells, animals or humans. Used as tracer molecules, they map the distribution, uptake and metabolism of the molecule in clinical studies, basic research or applied research. The area of radiopharmaceuticals is expanding rapidly. The number of PET centers in the world is increasing at 20% per year, and many drug companies are utilising PET and other forms of radiopharmaceutical imaging to evaluate products. * Readers will find coverage on a number of important topics such as radionuclide production, PET and drug development, and regulations * Explains how to use radiopharmaceuticals for the diagnosis and therapy of cancer and other diseases * The editors and a majority of the contributors are from the United States